• Home
  • Our Pipeline
  • About Us
  • Science
    • Active Immunotherapies
    • GlyMab®
  • News
  • Investors
    • Share Info
    • Financial Info
    • Documents & Presentations
    • Corporate Governance
  • Publications
  • Contact Us
    • Find a trial
    • Become an Investigator

An Immunohistochemical Evaluation of Tumor-Associated Glycans and Mucins as Targets for Molecular Imaging of Pancreatic Ductal Adenocarcinoma

by admin | Feb 14, 2022 | Antibodies, Glymab

Ruben D. Houvast, Kira Thijse, Jesse V. Groen, JiaXin Chua, Mireille Vankemmelbeke, Lindy G. Durrant, J. Sven D. Mieog, Bert A. Bonsing, Alexander L. Vahrmeijer, Peter J.K. Kuppen, A. Stijn L.P. Crobach and Cornelis F. M. Sier SIMPLE SUMMARY: Distinguishing pancreatic...

Targeting Glycans and Heavily Glycosylated Proteins for Tumor Imaging

by admin | Feb 14, 2022 | Antibodies, Glymab

Ruben D. Houvast, Mireille Vankemmelbeke, Lindy G. Durrant, Manfred Wuhrer, Victor M. Baart, Peter J.K. Kuppen, Lioe-Fee de Geus-Oei, Alexander L. Vahrmeijer and Cornelis F.M. Sier SIMPLE SUMMARY:  Distinguishing malignancy from healthy tissue is essential for...

Update on COVIDITY Phase 1 clinical trial in South Africa

by admin | Jan 31, 2022 | Covid-19, Latest News, Regulatory News

Welcome to WordPress. This is your first post. Edit or delete it, then start writing!

Interim Results for the 6 months ended 31 October 2021

by admin | Jan 26, 2022 | Regulatory News

Interim Report 31st October 2021

by admin | Oct 31, 2021 | Financial Info

Welcome to WordPress. This is your first post. Edit or delete it, then start writing!
« Older Entries
Next Entries »

Recent Posts

  • Scancell Receives FDA Fast Track Designation for iSCIB1+
  • Scancell announces CFO Transition
  • Edison Report – Redesigning immunity: The next frontier in immuno-oncology
  • Scancell Financial Year 2026 Interim Results
  • H126: solid iSCIB1+ data underpins planned progress

Recent Comments

No comments to show.

Scancell is focused on developing novel immunotherapies for the treatment of cancer and was founded in 1996 based on research led by Professor Lindy Durrant at the University of Nottingham in the UK.

  • Follow
  • Follow

About Us
Leadership Team
Science
Our Pipeline
News
Contact Us
Find a Trial
Become an Investigator

ACTIVE IMMUNOTHERAPY

ImmunoBody®
Moditope®

ANTIBODIES

GlyMab®
AvidiMab®

Investors
Company Profile
Advisors
Corporate Governance
Documents & Presentations
Share Information
Financial Information

Copyright © 2026 Scancell | Website Designed & Developed by Identity Creative | Privacy & Cookie Policy